About Coya Therapeutics, Inc.
https://www.coyatherapeutics.comCoya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
CEO
Arun Swaminathan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
DME CAPITAL MANAGEMENT, LP
Shares:1.65M
Value:$7.64M
GREENLIGHT CAPITAL INC
Shares:1.27M
Value:$5.91M
AIGH CAPITAL MANAGEMENT LLC
Shares:1.11M
Value:$5.13M
Summary
Showing Top 3 of 41
About Coya Therapeutics, Inc.
https://www.coyatherapeutics.comCoya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.56M ▲ | $5.47M ▼ | $-2.12M ▲ | -59.36% ▲ | $-0.13 ▲ | $-2.11M ▲ |
| Q2-2025 | $163.62K ▼ | $6.57M ▲ | $-6.09M ▲ | -3.73K% ▼ | $-0.36 ▲ | $-6.09M ▲ |
| Q1-2025 | $257.88K ▲ | $2.72M ▲ | $-7.31M ▼ | -2.83K% ▲ | $-0.44 ▼ | $-7.67M ▼ |
| Q4-2024 | $1.95K ▲ | $2.14M ▼ | $-2.92M ▲ | -149.37K% ▼ | $-0.18 ▲ | $-4.07M ▲ |
| Q3-2024 | $0 | $2.23M | $-4.02M | 0% | $-0.26 | $-4.44M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $28.13M ▼ | $32.04M ▼ | $4.76M ▼ | $27.28M ▼ |
| Q2-2025 | $29.76M ▼ | $33.45M ▼ | $5.14M ▲ | $28.31M ▼ |
| Q1-2025 | $35.53M ▼ | $38.4M ▼ | $5.04M ▲ | $33.37M ▼ |
| Q4-2024 | $38.34M ▲ | $44.35M ▲ | $4.77M ▲ | $39.58M ▲ |
| Q3-2024 | $31.06M | $35.55M | $3.54M | $32.01M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.12M ▲ | $-1.13M ▲ | $-516K ▼ | $19.14K ▲ | $-1.63M ▲ | $-1.13M ▲ |
| Q2-2025 | $-6.09M ▲ | $-5.77M ▲ | $0 | $0 ▼ | $-5.77M ▲ | $-5.77M ▲ |
| Q1-2025 | $-7.31M ▼ | $-2.83B ▼ | $0 | $19.14M ▲ | $-2.81B ▼ | $-2.83B ▼ |
| Q4-2024 | $-2.92M ▲ | $-2.41M ▲ | $0 | $9.69M ▲ | $7.28M ▲ | $-2.41M ▲ |
| Q3-2024 | $-4.02M | $-5.46M | $0 | $-56.33K | $-5.52M | $-5.46M |
CEO
Arun Swaminathan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
DME CAPITAL MANAGEMENT, LP
Shares:1.65M
Value:$7.64M
GREENLIGHT CAPITAL INC
Shares:1.27M
Value:$5.91M
AIGH CAPITAL MANAGEMENT LLC
Shares:1.11M
Value:$5.13M
Summary
Showing Top 3 of 41